Comparing Benefit and Costs for Abiraterone and Enzalutamide in Hormone-Sensitive and Castrate-Resistant Metastatic Prostate Cancer

[cujoe]

Summary article from MedPage Today's 'ASCO Reading Room'. Too bad our heath care comes down to cost-benefit analysis.

From the article:

"Ultimately, abiraterone and enzalutamide provide clinical benefit across all approved settings and have higher cost when used earlier in the course of metastatic prostate cancer. Value frameworks only contribute to, rather than completely define, the value of cancer therapies, and therefore additional measures will be needed to fully characterize value in cancer care."

Link to article:

Comparing Benefit and Costs for Abiraterone and Enzalutamide in Hormone-Sensitive and Castrate-Resistant Metastatic Prostate Cancer

medpagetoday.com/reading-ro...?

And here is a link to a MedPageToday interview with one of the research authors:

Srikala Sridhar, MD, on Abiraterone and Enzalutamide in Advanced Prostate Cancer

medpagetoday.com/asco/non-p...?

Stay Well - K9